Skip to content
value.today

Provell Pharmaceuticals, LLC

Formerly Provell II, LLC

Total raised
$12 M
5 rounds on record
Latest round
$1 M
Aug 2023
First round on record
Oct 2013
Today
Private
No later event on record

Funding rounds

5 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Provell Pharmaceuticals, LLC
MonthRaisedRaiseSizeInvestorsSoldFiling
Aug 2023$1 MNo. 5Under $2 million

Provell Pharmaceuticals, LLC: Raise no. 5, Aug 2023

Investors in this round

1 investor had bought by the notice of Aug 15, 2023: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $1 M offered
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, other: Convertible Note that converts into membership interest of Issuer in accordance with the terms therein.
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Limited Liability Company, incorporated in Pennsylvania

People named in the notice

  • James G. Small · Executive Officer

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Mr. Small will be entitled to fees for his services as Manager of Issuer in such amounts as may be approved by the Board of the Issuer. However, no one will receive any sales commission or finders fees in connection with this offering.”

Signed by James G. Small, Manager. Source: SEC Form D, newest notice filed Aug 15, 2023. Read the notice at the SEC.

debt, optionsSEC
Mar 2023$2 MNo. 4$2 to $10 million

Provell Pharmaceuticals, LLC: Raise no. 4, Mar 2023

Investors in this round

1 investor had bought by the notice of Mar 28, 2023: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Limited Liability Company, incorporated in Pennsylvania

People named in the notice

  • James G. Small · Executive Officer

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Mr. Small will be entitled to fees for his services as Manager of Issuer in such amounts as may be approved by the Board of the Issuer. However, no one will receive any sales commission or finders fees in connection with this offering.”

Signed by James G. Small, Manager. Source: SEC Form D, newest notice filed Mar 28, 2023. Read the notice at the SEC.

equitySEC
Jun 2022$2 MNo. 3$2 to $10 million

Provell Pharmaceuticals, LLC: Raise no. 3, Jun 2022

Investors in this round

1 investor had bought by the notice of Jul 11, 2022: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Limited Liability Company, incorporated in Pennsylvania

People named in the notice

  • James G Small · Executive Officer

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Mr. Small will be entitled to fees for his services as Manager of Issuer in such amounts as may be approved by the Board of the Issuer. However, no one will receive any sales commission or finders fees in connection with this offering.”

Signed by James G. Small, Manager. Source: SEC Form D, newest notice filed Jul 11, 2022. Read the notice at the SEC.

equitySEC
Jun 2019$2 MNo. 2$2 to $10 million

Provell Pharmaceuticals, LLC: Raise no. 2, Jun 2019

Investors in this round

1 investor had bought by the notice of Jul 10, 2019: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Limited Liability Company, incorporated in Pennsylvania

People named in the notice

  • James G. Small · Executive Officer · Manager, President and Chief Executive Officer

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Mr. Small will be entitled to fees for his services as Manager of Issuer in such amounts as may be approved by the Board of the Issuer. However, no one will receive any sales commissions or finders fees in connection with this Offering.”

Signed by James G. Small, Manager. Source: SEC Form D, newest notice filed Jul 10, 2019. Read the notice at the SEC.

equitySEC
Oct 2013$5 MNo. 1$2 to $10 million

Provell Pharmaceuticals, LLC: Raise no. 1, Oct 2013

Investors in this round

1 investor had bought by the notice of Dec 3, 2013: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $5 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Limited Liability Company, incorporated in Pennsylvania

People named in the notice

  • James G. Small · Executive Officer · Manager, President, and Chief Executive Officer

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Mr. Small will be entitled to fees for his services as Manager of Issuer in such amounts as may be approved by the Board of Issuer.”

Signed by James G. Small, Manager. Source: SEC Form D, newest notice filed Dec 3, 2013. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Provell Pharmaceuticals, LLC chose not to state its revenue in its newest notice of a funding round (Aug 2023).

    SEC Form D · Aug 2023

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Aug 2023

That is all the official record says: Provell Pharmaceuticals, LLC has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Provell Pharmaceuticals, LLC is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 5 rounds above had up to 1 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Provell Pharmaceuticals, LLC
NameRoleNamed in
James G. SmallExecutive officerAug 2023
James G SmallExecutive officerJul 2022